Genetic Technology--Patent Trends across Gene Editing

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology Technology Opportunity Engine (TOE) depicts the current landscape and the new life sciences trends across Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing mechanisms and cell therapies. The study covers the institutions involved in the CRISPR patent battle and the licensing agreements evolved through CRISPR-Cas9 patent scenario, as well as, the first stem cell-based therapy approved in Europe and antigen-specific T cell platforms for development of cell therapies. The corresponding analyst insights on gene editing patents, the overall patent scenario, along with the industry interactions, are exhibited.The Genetic Technology TOE presents the

Table of Contents

Genetic Technology--Patent Trends across Gene EditingTrend-Based Technology ProfilesInstitutions Involved in the CRISPR Patent Battle License Agreements Evolved through CRISPR-Cas9 Patent ScenarioRepercussions of CRISPR Patent Battle across other Regions Innovations that Stemmed off CRISPR- Cas9Strategic PerspectivesStrategic PerspectivesAppendixPatent ScenarioPatent Scenario (continued)Industry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.